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Abstract: Background: The incidence and mortality of intrahepatic cholangiocarcinoma (ICCA)
is increasing worldwide and curative treatment options are limited due to the aggressive tumor
biology and often late diagnosis. Resection of the primary tumor remains the only curative therapy
available, as the benefit of palliative chemotherapy and radiotherapy is relatively small. In contrast
to hepatocellular carcinoma, minimal-invasive thermal tumor ablation, and in particular stereotactic
tumor ablation for small primary cancers or metastases, is not established and data are scarce.
Methods: We conducted a literature review in the field of ICCA ablation and retrospective analysis
of 10 patients treated by stereotactic microwave ablation (SMWA) for either primary ICCA or liver
metastases of ICCA. Results: While current guidelines have no consensus for ablation of primary
ICCA, some state that it might be an option in inoperable patients or those with recurrent disease.
The literature review revealed 11 studies on microwave ablation for ICCA reporting that MWA for
ICCA ≤ 5 cm might be safe and could be a treatment option for patients who are not candidates for
surgery. No data has been published on stereotactic microwave ablation (SMWA) for ICCA. The
analyses of our own data of 10 patients treated by SMWA for primary ICCA (n = 5) or recurrent ICCA
(n = 5) show that the treatment is safe and efficient with short hospital stays and low complication
rates. Conclusion: Although thermal ablation, and in particular SMWA, might be a minimally
invasive and tissue-sparing curative treatment alternative for small ICCA in the diseased liver and
ICCA metastases, the oncologic benefit still needs to be shown in larger studies with longer follow-up.
Keywords: computer-assisted ablation; stereotactic ablation; intrahepatic cholangiocarcinoma;
minimal-invasive liver treatments; microwave ablation
1. Introduction
Cholangiocarcinoma (CCA) is the second most common liver cancer worldwide and
accounts for about 15% of all primary liver tumors [1]. The incidence is increasing over the
last decades with 0.3–6 cases per 100,000 people per year [2]. Intrahepatic cholangiocarcino-
mas (ICCA) arise distal to the second-order bile ducts and can be clearly distinguished from
perhilar and hilar cholangiocarcinomas [3]. While most known risk factors for ICCA are in
one way or another associated with chronic inflammation of the bile ducts, chronic liver
disease (cirrhosis, viral hepatitis) and physiochemical irritation [4], and patient-related
factors such as diabetes, obesity, smoking, hypertension and alcohol consumption have
also been described [1,3]. The treatment of choice is surgery; however, a resection is only
feasible in 20–40% of cases [5–7]. There is a high recurrence rate after a successful resec-
tion (60%) and the 5-year survival rate after surgery is only 20–44% if the tumor can be
resected with a clear safety margin [8–10]. If the operation cannot be completed with clear
margins, the 5-year survival drops to 0% [11]. In addition, patients with positive lymph
nodes only have a 5-year survival of 0–9% compared with 43% in patients with no lymph
node metastases [12]. Liver transplantation might be a treatment option in patients with
limited disease and underlying cirrhosis, but data are rare and results from ongoing clinical
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trials are urgently awaited. While palliative treatments (chemotherapy, radiotherapy) have
limited effect on these tumors with a median survival around 5–8 months [13,14], some
new targeted treatment options show promising first results [15–17]. The therapeutic
resistance of ICCA is based on the genetic heterogeneity, the highly desmoplastic nature
and complex tumor microenvironment in the liver [18]. Thermal ablation, such as mi-
crowave ablation (MWA) and/or radiofrequency ablation (RFA), has become an important
curative treatment option for hepatocellular carcinoma (HCC), but data for ICCA are very
limited. Ablation has the advantage of being minimally invasive and tissue sparing, also in
non-surgical candidates or those with underlying liver disease [19]. MWA seems to have
several advantages over RFA including higher intra-tumoral temperatures, larger ablation
volumes, shorter operation times and less dependence on the electrical conductivity of
tissues [20,21].
Recently, computer-assisted navigation systems have been introduced to increase
the efficacy and safety of liver tumor ablations and to increase the feasibility of tumor
ablation for lesions in difficult to treat anatomic locations [19]. Several studies have now
demonstrated the safe clinical application of these systems in particular for HCC and liver
metastases, but not much is known for ICCA.
Herein, we aim to summarize the current literature on computer-assisted and conven-
tional ICCA ablation and present our own clinical data of stereotactic microwave ablation
(SMWA) for ICCA primary tumors and ICCA metastases.
2. Materials and Methods
A systematic literature search was performed using PubMed, OVID MEDLINE, EM-
BASE, Scopus and Cochrane library with the mesh terms: intrahepatic cholangiocarcinomas
(all fields) AND microwave ablation (all fields). We found 261 matches. All titles and
abstracts were screened and after exclusion of papers not published in English, case reports,
book chapters and letters, we excluded 65 review papers. We analyzed 12 papers (Figure 1).
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3. Results
3.1. Current Guideline Recommendation for ICCA Ablation
Most of the current guidelines for the treatment for ICCA give no specific treatment
recommendation for ICCA ablation. The European Society of Medical Oncology (ESMO)
guidelines only mention radiotherapy and Y90 radioembolization for irresectable or locally
advanced and non-metastatic tumors [22]. The British Society of Gastroenterology (BSG)
guideline of 2012 suggests RFA as a safe treatment option for small, unresectable ICCA, but
there are no treatment recommendations for the use of MWA. Instead, they report the results
of a small Chinese study where 18 patients (8 primary and 10 recurrent cases after resection)
were treated with ultrasound-guided thermal ablation with curative intention showing
a complete ablation rate of 92% with an overall survival rate of 30% at 36 months [23].
The European Association for the Study of the Liver (EASL) guideline of 2014 state that
a small group of patients with liver-only recurrence may be treated by either ablation or
resection [24]. In addition, the latest National Comprehensive Cancer Network (NCCN)
guideline from 2021 only gives a weak recommendation for loco regional therapies such
as RFA and TACE in patients with unresectable tumors or metastatic cancer without
extrahepatic disease [25]. Overall, there are no established first-line ablation options for
patients with resectable and unresectable ICCA or ICCA metastases. Ablation approaches
may be considered for small and single lesions in individual cases.
3.2. MWA for ICCA
Although MWA is an efficient therapy for HCC, this technique is not very common for
the treatment of ICCA and only a few retrospective studies have been published (Table 1);
therefore, evidence is limited compared with HCC or colorectal liver metastasis treated
with MWA. Even though the selection bias in the published studies is high, most tumors
were treated in curative intent and not in a palliative setting. In case of recurrence after
ICCA resection, ablation was also performed in curative intent and most studies excluded
patients with extrahepatic disease.
Table 1. Summary of the literature on MWA for ICCA.
Reference of
Original
Publication
Year of
Publication
Technique(s)
Analyzed
Number of
Patients
Included
Number of
Treated
Lesions
Size
(Range; cm)
OS
1, 3, 5 Years (%)
RFS
1, 3, 5 Years
(%)
[26] 2011 MWA 15 24 3.2 (1.3–9.9) 60, -, - -
[23] 2012 MWA 18 (6) 25 2.5 (0.7–4.3) 36.3, 30.3, 30.3 -
[27] 2015 MWA/TACE 26 39 3.6 (2.5–6.5) 69.2, 61.5, - -
[28] 2018 MWA 107 171 93.5, 39.6, 7.9 41.5, -, -
[29] 2018 RFA vs. MWA 20 50 1.8 (0.5–4.7) - -
[30] 2019 RFA vs. MWA 71 (35) 98 (50) 3.6 ** (2.2–7.2) 95, 75, 68 ** 79, 59, 55 **
[31] 2019 MWA 78 106 3.1 (0.8–5) 78.9, 52.2, 35 78.9, 19.9, -
[32] 2019 MWA vs.surgery 121 (56) 136 (62) 2.7 (0.8–5) 81.2, 42.5, 23.7 ** 70.3, 33.1, - **
[33] 2020 MWA/TACE 275 (92) - 5.7 50, 21.5, 6.1 41.1, 21.5, 6.1
[34] 2020 MWA 221 {32} 285 - - -
[35] 2020 MWA/RFA 27 (3) * 33 2.1 (2.0–2.8) 88.9, 40.7, 14.8 -
[36] 2021 MWA 52 74 3.1 (0.8–5) 87.4, 51.4, 35.2 68.9, 56.9, 56.9
MWA = microwave ablation; RFA = radio radiofrequency ablation; TACE = transarterial chemoembolization; OS = overall survival, RFS:
recurrence free survival. * Results for different ablation, not separated; ** Results for MWA; () = CCA; { } = ICCA.
One of the first papers, investigating MWA for ICCA included 15 patients with primary
ICCA [26]. The success rate of the treatment was 91.7% and the local tumor progression
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rate was 25%. The cumulative overall survival rate for 6, 12 and 24 months were 78.8%,
60.0% and 60.0%, respectively. Xu et al. published similar results after one year, including
18 patients: 8 with primary tumors and 10 with recurrent disease [23]. A few years later,
in 2017, one of the largest studies looking at MWA in ICCA was published by Zhang
et al. [28]. They included 107 patients with 171 lesions in curative intention. The lesions
were smaller than 5 cm, and the number of lesions per patient was ≤3. The median PFS
was in 8.9 months, the PFS rate after 6, 12, 18 and 24 months was 67.4%, 41.5%, 18.2% and
8.7%, respectively. The median overall survival was 28 months, and the OS rate after 1, 3
and 5 years was 93.5%, 39.6% and 7.9%, respectively. The group concluded that MWA for
ICCA ≤5 cm is safe as a treatment option in patients who are not candidates for surgery.
Two studies looked at the outcomes of ICCA after MWA based on Albumin–Bilirubin grade
(ALBI) [31,36]. The ALBI was used as a predictive value for long-term overall survival after
MWA in ICCA patients. The ALBI grade may offer a prognostic tool to evaluate patients
for MWA in early ICCA. Additionally, in these studies the OS was similar to other studies
(1-, 3- and 5-year OS: 87.4%, 51.4% and 35.2%, respectively). Most of the included studies
did not specifically address the effect of neo-adjuvant or adjuvant chemotherapy. Yang et al.
reported 11 patients who received an adjuvant therapy with gemcitabine and cisplatin after
MWA but did not stratify the results accordingly [31]. Only the work by Takahashi et al.
showed that a neo-adjuvant treatment with chemotherapy did not reduce the risk for local
tumor progression [32].
3.3. Ablation vs. Surgery
There was one study comparing ultrasound-guided MWA vs. surgery retrospec-
tively [35]. In this study, 121 consecutive patients were included, 56 with MWA (62 lesions)
and 65 with surgical resection (74 lesions). Both techniques had a success rate of 100%.
The difference in recurrence rates was not significant (9/56 vs. 8/65). There was also no
difference in the 1-, 3- and 5-year OS. The authors concluded that ablation had the same
efficacy as surgery for recurrence and should be preferred in patients with liver function of
ALBI grade 2 [35].
3.4. RFA vs. MWA
There are several studies comparing RFA and MWA. In 2018 Takahashi et al. reported
the results of a small retrospective study, analyzing 20 patients with 50 lesions [32]. They
performed percutaneous RFA (44 patients) and only four MWA. The tumor size in both
treatment groups was very small with a mean size of 1.8 cm. A larger, multicenter study
was done in Italy, also comparing the two techniques. In total, 71 patients were treated,
including 36 with RFA and 35 with MWA [29]. They concluded that patients treated with
MWA for ICCA nodules <3 cm survived longer than patients treated with RFA (p < 0.005).
The OS in the MWA group was 95%, 75%, 68% and 68% at 12, 36, 60 and 80 months, and
86%, 53%, 26% and 13% in the RFA group, respectively, (p < 0.005). Additionally, the
progression-free survival was higher in the MWA group compared with the RFA group,
with 79%, 59%, 55% and 55% at 12, 36, 60 and 80 months in the MWA group, respectively,
and 69%, 51%, 8.5% and 8.5% at 12, 36, 60 and 80 months in the RFA group, respectively.
Another study looked at the topic of thermal ablation for ICCA in cirrhosis [30]. They
included patients with 27 patients with ICCA, Child A/B without ascites/encephalopathy
and with cirrhosis and performed RFA or MWA. In conclusion, they reported that thermal
ablation is also safe and effective in treatment for ICCA in patients with liver cirrhosis [30].
3.5. MWA and TACE
As known from HCC, MWA combined with transarterial tumor embolization results
in a high complete response rate, in particular in larger tumors [37,38]. A group in China
conducted a retrospective analysis of the efficacy of percutaneous microwave ablation
combined with simultaneous transarterial chemoembolization (TACE) [39]. They included
26 patients in their study, including 20 primary tumors, and 6 with recurrence after surgery.
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The treated tumors were 3.6 ± 1.1 cm in patients with Child A or B. The median progression
free survival was 6.2 months with an OS at 12 and 24 months of 69% and 62%, respectively.
Another group from Ge et al. analyzed 275 patients with recurrent ICC comparing TACE
vs. MWA. The treated tumors were 6.5 ± 3.7 for TACE and 5.7 ± 2.4 cm for MWA. In their
study, TACE provided a higher survival benefit.
3.6. Stereotactic Microwave Ablation (SMWA)
One study from Germany compared the efficacy of stereotactic MWA with conven-
tional free-hand MWA of malignant liver tumors [40]. They included 221 patients with
30 patients with ICCA. While the stereotactic navigation improved primary efficacy com-
pared to conventional guidance (84.3% vs. 75.0%), no specific data were given on the results
of the treated ICCAs.
3.7. ICCA and Stereotactic MWA: Clinical Trials
Up until today, no randomized controlled or other clinical trials have been performed
to analyze the efficacy of stereotactic MWA (SMWA) for ICCA. Currently, ClinicalTrials.gov
has five trials registered for the treatment of ICCA (05/2021). While one is a registry, three
are analyzing the combination of ablation with systemic treatments, one is studying RFA
for all biliopancreatic malignancies and one is examining a novel RFA device for other liver
malignancies as well. No study is currently ongoing analyzing the effect of SMWA or other
computer-assisted navigation devices for the treatment for ICCA.
3.8. Own Patients with ICCA Treated by SMWA
During the past three years, we performed SMWA for 10 patients with ICCA. Five
patients had primary ICCA and underlying liver disease, five patients had metastatic
disease after previously resected ICCA in healthy livers. Table 2 summarizes the results of
the five patients treated by SMWA for primary ICCA. While three patients were treated
for a suspected HCC and had an incidental finding of ICCA in the biopsy, two patients
were diagnosed before SMWA. One patient developed a local recurrence after 18 months
and is now planned for a combined treatment of embolization and ablation. Another
patient was transplanted 10 months after the ablation showing no disease recurrence in
the explanted liver or afterwards. Table 3 gives an overview of the patients treated with
SMWA for recurrent ICCA. While three patients are currently tumor free, two developed
local recurrences and simultaneous overall disease progression leading to tumor-related
mortality. One patient died without disease recurrence. Figure 2 gives an example of one
patient with recurrent ICCA treated by SMWA. SMWA allows for a tumor segmentation and
planning of the ablation zone, a precise placement of the ablation probe and an immediate
validation of the ablation zone in respect to the tumor within the intervention. In case of
invisibility of the tumor, the pre-interventional MRI images can be fused with the CT-scan
for the treatment.
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Table 2. Patients with primary ICC treated by SMWA.
Patient Age atSMWA Gender
Child
Score
Underlying
Liver Disease Segment
Tumor Size
(mm)
Previous
Treatment
Complications
> Dindo IIIa
Local
Recurrence
Time to
Recurrence
(Months)
Treatment of
Recurrence Death
OS
(Months)
Time to
Transplant
(Months)
Overall
Disease
Progression
1 31 M B7 PSC V 20 no no no no 31.5 10 no
2 58 M A6 HCV VIII 23 no no yes 18 TAE + MWAplanned no 19 N/A no
3 64 M A6 ASH/NASH VIII 15 TAE no no no 12 N/A no
4 58 M A5 NASH VI 24 no no no no 10 on waiting list yes (HCC)
5 81 M A5 Unknown V/VIII 27 No no no no 6 no
Gender: M = male, F = female; OS = overall survival; HCV = hepatitis C; PSC = primary sclerosing cholangitis; TAE = transarterial embolization; ASH = alcoholic steatohepatitis; NASH = non-alcoholic
steatohepatitis.
Table 3. Patients with ICC metastases treated by SMWA.
Patient Age at SMWA Gender Tumor Stage Previous Treatment Adjuvant CTX Location MetastasisSegment
Size of Ablated
Metastasis
Complications >
Dindo IIIa
1 72 W T2aN1M0 L0V0Pn1 G1 R0 ALPPS Gemcitabine II 32 no
2 37 W T1N0M1 L0V0Pn0 R0 G3
Right hepatectomy +
metastectomy left
liver
Xeloda II 15 no
3 58 M T1N0M0 Ln1V0Pn0R1 G3 ALPPS Gemcitabine/Capecitabine IVb 26 & 25 no
4 66 W T2N0M0 Ln0V1Pn0R1 G2 Extended lefthepatectomy none VIII 17 no
5 56 M T2aN0M0 Ln0V0Pn1R0 G1 ALLPS none III 6 abscess
Patient LocalRecurrence
Time to Recurrence
(Months) Treatment of Recurrence Death
OS after SMWA
(Months)
OS after
Initial Diagnosis Overall Disease Progression
1 yes 5 SBRT yes 19 45 yes
2 no no 20 34 no
3 yes 3 CTX yes 5.5 35 yes
4 no yes 6.5 15 no
5 no no 1 25 no
Gender: M = male, F = female; OS = overall survival; CTX = chemotherapy; SBRT = stereotactic body radiotherapy; ALPPS = Associating Liver Partition and Portal Vein Ligation.
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Figure 2. (A) Pre-interventional MRI imaging reveals the metastasis with high signal in the b800 image of the diffusion-
weighted imaging (DWI) and also shows (B) a lack of intracellular uptake of hepatocyte-specific contrast medium in the
hepatobiliary phase. (C) The pre-interventional planning of the ablation zone (red circle = segmented tumor; (D) green
circle = anticipated ablation zone) needle validation scan with the needle in place and the anticipated ablation zone in green.
(E) The ablation zone in the contrast-enhanced control scan; (F) needle in place.
4. Discussion
MWA and SMWA are not established therapies for the treatment of ICCA. Up until
now, only very limited data are available on the safety and efficacy of conventional image-
guided ICCA ablation in general, and no specific data are available for the use of computer-
assisted navigation approaches, in particular not for SMWA.
There is no consensus for the use of ablation for ICCA and current guidelines report
different treatment recommendations [22,24,41]. While some recommend the use of ab-
lation for irresectable or recurrent tumors, no guideline recommends ablation as a first
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line treatment. Due to the small number of reported cases of only retrospective nature, the
evidence for all of these recommendations is rather small.
Our literature research revealed 11 papers analyzing the effect of microwave ablation
for ICCA showing that MWA is feasible and safe [23,26,28,31,36]. The studies were all
done retrospectively with small patient numbers. MWA was used in patients with primary
tumors, who are not surgical candidates or with recurrent tumors. Despite the small
cohorts and the retrospective design of the studies, the general conclusion of these papers
was that MWA might prolong the overall survival of patients and that it could be more
effective than RFA. Overall, it seems that most of these studies focus on ICCAs developing
in cirrhosis, often even detected incidentally since HCC was suspected and led to the
treatment recommendation of ablation. Therefore, most data are of a retrospective nature,
analyzing the results after incidentally detected and already treated tumors.
Not much is known about the efficacy of MWA for the treatment of primary ICCA
in the healthy liver or for the treatment of recurrent disease, in particular because these
tumors are often diagnosed at advanced stages and treated by major liver resections or
systemic therapy [42]. Since ablation is still limited to tumors <3 cm, with some studies
now showing efficacy for the treatment of HCCS 3–5 cm [43], the role for the primary
treatment of ICCA in the healthy liver is rather negligible. Patients with recurrent ICCA
in the healthy liver are mostly treated by chemotherapy or re-resection, and ablation is
usually only recommended in individual cases discussed in the tumor board. A potential
advantage is the fact that ablation can be carried out while chemotherapy is performed.
Next generation sequencing (NGS) is currently changing the treatment regime for ICCA
with new treatments for the recently detected mutations IDH1 and FGFR2 (Ivosidenib and
Pemigatinib) showing promising results [44]. If these modern treatment approaches based
on NGS continue to show their efficacy in ICCA patients [3] and if an additive treatment by
ablation improves, the outcome still needs to be analyzed. Patients with recurrent disease
in cirrhosis often have limited systemic treatment options due on the underlying liver
disease [45] and might therefore be ideal candidates for a treatment with ablation.
The role for the combination of ablation with embolization therapy for ICCA still
needs to be explored and most likely depends on the underlying tumor biology. Some
initial reports suggest that there might be role for this approach in tumors >3 cm and
inoperable or unresectable patients [39].
As known from HCC and other liver tumors routinely treated by ablation, the use
of image-guided computer-assisted navigation is safe and efficient and helps to increase
the number of treatable tumors by facilitating ablation in difficult anatomic locations
of the liver, for tumors close to important vasculature or adjacent organs or even those
invisible on ultrasound and CT [19]. In addition, these technical advancements optimize
the treatment by including an ablation planning and validation software allowing doctors
to precisely plan the ablation zone and to immediately validate the results in the control
scan during the intervention. While there are only very limited data available on the use of
computer-assisted image-guided navigation for the treatment of ICCA [40], we can herein
report our initial experience with 10 patients with SMWA showing that this approach is
safe and efficient and might be a treatment alternative to resection or systemic treatment
in individual cases. Clearly more data are urgently needed and indications for primary
ICCA in the cirrhotic liver, primary ICCA in the healthy liver and ICCA recurrence or their
metastases, should be analyzed separately.
5. Conclusions
Although prospective data of ICCAs treated by ablation and in particular SMWA are
still lacking, this minimally invasive and tissue-sparing therapeutic option might be a safe
and efficient treatment alternative for small primary ICCA as well as for metastatic ICCA
in individual patients.
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